The Society for Immunotherapy of Cancer (SITC) published it's first clinical practice guideline (CPG) on immunotherapy for the treatment of patients with hematologic malignancies in the Journal for ImmunoTherapy of Cancer, on December 20, 2016.
Since 2016, the rapid pace of progress in the field motivated the formation of three new Expert Panels to develop standalone guidelines for individual disease states: acute leukemia (published October 19, 2020), lymphoma (published December 24, 2020), and multiple myeloma (published July 12, 2020).
SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The Hematologic Malignancies CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG provides recommendations for the use of immunotherapies that include monoclonal antibodies, checkpoint inhibitors, CAR T cells, NK Cells and immunotherapeutic vaccines.